Panniculitis

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

Retrieved on: 
Monday, June 5, 2023
Histology, Safety, Incidence, Division, Kruskal–Wallis one-way analysis of variance, Carcinoma, Dunn, Observation, RNA interference, LSR, University, Diet, Therapy, Genetics, Ageing, Abdominoplasty, Behzad Razavi, Plastic, Fat necrosis, FDA, BCC, Skin, Exercise, Injection, Interim, Bruise, Erythema, Research, Panniculitis, Edema, Clinical trial, RNA, Trial of the century, Causality, Abdomen, Pharmaceutical industry, Dietary supplement

The initial results of the Phase I trial appear to indicate that the use of STP705 in the treatment of unwanted fat is safe and show clear signs of efficacy.

Key Points: 
  • The initial results of the Phase I trial appear to indicate that the use of STP705 in the treatment of unwanted fat is safe and show clear signs of efficacy.
  • This interim efficacy results examined efficacy data from six participants that were scheduled to undergo abdominoplasty.
  • The positive interim results have better informed the Group about the later stage development of STP705 in the medical aesthetics category.
  • "The interim results of this Phase I clinical study have brought a strong enthusiasm using RNAi drug for medical aesthetic treatment.

Alpha-1 Antitrypsin Deficiency Market Research Report 2022: Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 9, 2022
Health, General Health, Respiratory disease, COPD, Panniculitis, Clinical trial, Blood, AGR, Inflammation, Vasculitis, Epidemiology, AATD, Therapy, Risk, Review, AAT, Diagnosis, RNA interference, NE, Prevalence, Liver, Population growth, Industry, CAGR, Oil, Pharmaceutical industry

The "Alpha-1 Antitrypsin Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alpha-1 Antitrypsin Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The 2MM market (US and Germany) is expected to grow from $1.2 billion in 2021 to $3.48 billion in 2031 at a CAGR of 11.2%.
  • The introduction of 4 new pipeline agents are key drivers of this market growth.
  • The most promising candidates in late-stage development are profiled
    Analysis of the current and future market competition in the global AATD therapeutics market.